Live Breaking News & Updates on Kiniksa Pharmaceuticals Ltd|Page 5

Stay updated with breaking news from Kiniksa pharmaceuticals ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Sanjk Patel , Rachel Frank , Globenewswire Inc , Exchange Commission , Kiniksa Pharmaceuticals Ltd , Abiprubart Phase , Chief Executive Officer , Clinical Trial , Syndrome Disease Activity Index , Least Squares , Disease Activity Score , Usingc Reactive Protein , Rheumatoid Factor ,

Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA), a biopharmaceutical company focused on the discovery, acquisition, development, and commercialization of therapeutics for patients suffering from debilitating diseases with significant unmet medical need, has reported an insider sale according to a recent SEC filing. ....

Kiniksa Pharmaceuticals Ltd ,

Wedbush Weighs in on Kiniksa Pharmaceuticals, Ltd.'s Q1 2025 Earnings (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) – Equities research analysts at Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Kiniksa Pharmaceuticals in a research note issued to investors on Wednesday, February 28th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.17) per share for the quarter. Wedbush […] ....

Johnf Paolini , Mark Ragosa , Kiniksa Pharmaceuticals Ltd , Kiniksa Pharmaceuticals Company Profile , News Ratings For Kiniksa Pharmaceuticals Daily , Altshuler Shaham Ltd , Kiniksa Pharmaceuticals Price Performance , China Universal Asset Management Co , Kiniksa Pharmaceuticals , Securities Exchange Commission , Royal Bank , Advisors Inc , Lazard Asset Management , Free Report , Kiniksa Pharmaceutical , Asset Management , Shaham Ltd , China Universal Asset Management , Universal Asset Management , Exchange Commission , Get Free Report , Kiniksa Pharmaceuticals Daily , Nasdaq Knsa , Earnings Estimates ,

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Sets New 1-Year High at $20.94

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $20.94 and last traded at $20.83, with a volume of 197612 shares traded. The stock had previously closed at $20.16. Analyst Ratings Changes KNSA has been the topic of […] ....

Johnf Paolini , Michaelr Megna , Tower Research Capital , Altshuler Shaham Ltd , News Ratings For Kiniksa Pharmaceuticals Daily , Lazard Asset Management , Kiniksa Pharmaceuticals Stock Performance , Kiniksa Pharmaceuticals Ltd , Royal Bank , Securities Exchange Commission , Advisors Inc , Kiniksa Pharmaceuticals , Get Free Report , Exchange Commission , Research Capital , Asset Management , Shaham Ltd , Kiniksa Pharmaceuticals Daily , Nasdaq Knsa ,